Raúl Sánchez, general manager of Peri Logistics speaks about
In Conversation
of Andrómaco Laboratories. The acquisition has been a major step in Grunenthal’s growth strategy and has almost doubled its revenues in Latin America.
“70 percent of products on the Chilean market cannot demonstrate quality, safety and efficacy through bioequivalence studies”, explains Jean Jacques Duhart,
Rodrigo Azócar Ibaceta, general manager at
Erich Viertel Molina, country manager at Janssen Chile speaks about Janssen’s commitment to the health of Chileans.
Pfizer will invest in a precision medical center studying new genome-based diagnostic technologies for cancer in Chile.
Our business model is new in the Chilean market and enables us with great flexibility and allows us to focus on demand generation. For Ferrer this…
PMG Pharma, a niche player, with
Sebastián Araya van der Schraft, General Manager at Laboratorio Kampar S.A. discusses the new medicine law in Chile—considered a victory by the last government—and further explains…
The Chilean operations for Hospira also manage the Argentine and Uruguayan operations of the company. What led to the decision of choosing Chile as the HQ…
Lilly’s portfolio ranges from products for cardiovascular diseases to neurological conditions. How has your portfolio developed in Chile? What therapeutic areas is Lilly favoring in the…
How would you assess Roche’s performance in Chile since its establishment and how has your portfolio developed in the Chilean market? Next year marks Roche’s 40th…
